The effects of quetiapine XR [extended-release] on cognition, mood and anxiety symptoms in SSRI [selective serotonin reuptake inhibitor]-resistant unipolar depression.

Trial Profile

The effects of quetiapine XR [extended-release] on cognition, mood and anxiety symptoms in SSRI [selective serotonin reuptake inhibitor]-resistant unipolar depression.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2010

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Planned end date changed from 1 May 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top